The $20.25/share all-cash offer at a 49% premium provides a clear near-term price target for ARX shares, which should trade near the offer price minus a small deal-risk discount. The stock will likely gap up toward $20.25 on the open. Key risks to monitor: insurance regulatory approval timeline (ticking fee of 6% per annum if delayed), potential competing bids given the strong Q2 results, and any shareholder litigation. The deal is fully financed and has 82% voting support, making completion highly probable. Traders should consider the narrow arbitrage spread and the expected close in H1 2027.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 13 $19.51entry
- T+1 · 3mo ago +0.36%α +0.56% · $19.58
- T+5 · 3mo ago +0.31%α +2.27% · $19.57
- T+20 · 2mo ago +1.69%α +3.44% · $19.84
- T+60 · 11d ago +1.95%α +7.42% · $19.89
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Accelerant Holdings announced a definitive agreement to be acquired by Thoma Bravo in an all-cash transaction valued at $20.25 per share, representing a 49% premium to the August 12, 2026 closing price and an enterprise value of more than $4 billion. The company also reported strong Q2 2026 results with Exchange Written Premium growing 23% YoY to $1.32 billion and adjusted net income increasing 165% to $70 million, but the take-private announcement overshadows the earnings release. The transaction is expected to close in the first half of 2027, subject to shareholder and regulatory approvals, with Altamont Capital Partners (holding ~82% voting rights) already committed to vote in favor.
Key Financial Metrics
Key Facts
- Accelerant entered a definitive merger agreement with Thoma Bravo to be taken private at $20.25 per share in cash, a 49% premium to the August 12, 2026 closing price.
- Enterprise value of the transaction is more than $4 billion.
- Altamont Capital Partners, holding ~82% of voting rights, has agreed to vote in favor of the transaction.
- Transaction is not subject to a financing condition; Thoma Bravo provided an equity commitment.
- Q2 2026 Exchange Written Premium grew 23% YoY to $1.32 billion.
- Adjusted net income increased 165% YoY to $70 million; adjusted EBITDA grew 46% to $93.1 million with a 30.6% margin.
- The company repurchased 4,725,968 Class A common shares for $66 million in Q2 2026.
- Accelerant will not provide Q3 or full-year 2026 guidance due to the pending transaction.
- Closing expected in the first half of 2027, subject to shareholder approval and regulatory clearances.
- Altamont Capital Partners and founders intend to retain equity ownership alongside Thoma Bravo.
Financial Impact
Shareholders receive $20.25 per share in cash, a 49% premium to the $13.59 closing price on August 12, 2026. Enterprise value exceeds $4 billion. Q2 2026 adjusted net income was $70 million (up 165% YoY) on operating revenues of $303.9 million.
Risk Factors
- Regulatory approval delays from insurance regulators could push closing beyond H1 2027.
- Shareholder litigation challenging the deal or seeking a higher price.
- Potential competing bid from another private equity firm given the strong operating momentum.
- Failure to obtain required shareholder approval (though 82% voting support mitigates this risk).
- Macroeconomic or industry disruption before closing could affect deal terms.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001193125-26-347928 |
| Document: 0001193125-26-347928-index-headers.html | 0001193125-26-347928 |
| Document: 0001193125-26-347928-index.html | 0001193125-26-347928 |
| Document: 0001193125-26-347928.txt | 0001193125-26-347928 |
Track record
29 reports on ARX
7 of 11 bullish or bearish reports moved the stock their way by T+5. Best: +43.47% at T+60 after the Feb 27, 2026 report. 8 of 11 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 3/10 Entry price pending
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $19.87 Now $19.85 −0.10% settles Nov 24
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $19.90 Now $19.85 −0.25% settles Nov 23
- Nov 12, 20264d ago 8-K Neutral 5/10 Entry $19.89 Now $19.85 −0.20% settles Nov 19
- Oct 30, 202617d ago SC 13E-3 Bullish 7/10 Entry $19.81 to $19.88 Now $19.85 +0.20% ▲ +0.35% +0.27% vs SPY
- Oct 30, 202617d ago PREM14A Neutral 6/10 Entry $19.81 to $19.88 Now $19.85 +0.20% ▲ +0.35% +0.27% vs SPY
- Sep 30, 20266w ago SC 13G Neutral 4/10 Entry $19.73 to $19.75 Now $19.85 +0.61% ▲ +0.10% −1.20% vs SPY
- Sep 23, 20267w ago 8-K Bullish 5/10 Entry $19.72 to $19.73 Now $19.85 +0.66% ▲ +0.05% +0.73% vs SPY
- Aug 14, 202613w ago Insider Cluster Bearish 6/10 Entry $19.54 to $19.66 Now $19.85 −1.59% ▼ −0.61% −1.80% vs SPY
- Aug 13, 202613w ago DEFA14A / 8-K Bullish 7/10 Entry $19.58 to $19.59 Now $19.85 +1.38% ▲ +0.05% +1.42% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers